CISH KNOCKOUT BY CRISPR/CAS9 ENHANCES HUMAN PERIPHERAL BLOOD -DERIVED NK CELL FUNCTIONS AGAINST ALLOGENEIC GLIOBLASTOMA

被引：0
|
作者：
Nakazawa, T. [1 ,2 ]
Morimoto, T. [1 ]
Maeoka, R. [1 ]
Matsuda, R. [1 ]
Nishimura, F. [1 ]
Tsujimura, T. [2 ,3 ]
Nakagawa, I. [1 ]
机构：
[1] Nara Med Univ, Neurosurg, Kashihara, Nara, Japan
[2] Grandsoul Res Inst Immunol, Uda, Japan
[3] Clin Grandsoul Nara, Uda, Japan
来源：
CYTOTHERAPY | 2024年 / 26卷 / 06期
关键词：
NK cells; CRISPR/Cas; glioblastoma;
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
978
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [1] CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
    Nakazawa, Tsutomu
    Morimoto, Takayuki
    Maeoka, Ryosuke
    Matsuda, Ryosuke
    Nakamura, Mitsutoshi
    Nishimura, Fumihiko
    Ouji, Noriko
    Yamada, Shuichi
    Nakagawa, Ichiro
    Park, Young Soo
    Ito, Toshihiro
    Nakase, Hiroyuki
    Tsujimura, Takahiro
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [2] CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
    Tsutomu Nakazawa
    Takayuki Morimoto
    Ryosuke Maeoka
    Ryosuke Matsuda
    Mitsutoshi Nakamura
    Fumihiko Nishimura
    Noriko Ouji
    Shuichi Yamada
    Ichiro Nakagawa
    Young Soo Park
    Toshihiro Ito
    Hiroyuki Nakase
    Takahiro Tsujimura
    Journal of Experimental & Clinical Cancer Research, 42
  • [3] Characterization of CISH-knockout NK cells derived from human peripheral blood and evaluated the antitumor effects in allogeneic glioblastoma
    Nakazawa, Tsutomu
    Morimoto, Takayuki
    Maeoka, Ryosuke
    Matsuda, Ryosuke
    Nishimura, Fumihiko
    Tsujimura, Takahiro
    Nakagawa, Ichiro
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [4] Determining the Impact of CRISPR/Cas9 Mediated AVIL Gene Knockout on Human Glioblastoma In Vitro
    Smith, J. E.
    Poudel, A.
    Srinageshwar, B.
    David, D.
    Swiontek, J.
    Dunbar, G.
    Rossignol, J.
    CELL TRANSPLANTATION, 2023, 32 : 24 - 24
  • [5] CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
    Guo, Xuan
    Mahlakoiv, Tanel
    Ye, Qian
    Somanchi, Srinivas
    He, Shuyang
    Rana, Hemlata
    DiFiglia, Andrea
    Gleason, Joseph
    van der Touw, William
    Hariri, Robert
    Zhang, Xiaokui
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [6] Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9
    Afolabi, Lukman O.
    Adeshakin, Adeleye O.
    Sani, Musbahu M.
    Bi, Jiacheng
    Wan, Xiaochun
    IMMUNOLOGY, 2019, 158 (02) : 63 - 69
  • [7] Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9
    Chen, Yuejun
    Cao, Jingyuan
    Xiong, Man
    Petersen, Andrew J.
    Dong, Yi
    Tao, Yunlong
    Huang, Cindy Tzu-Ling
    Du, Zhongwei
    Zhang, Su-Chun
    CELL STEM CELL, 2015, 17 (02) : 233 - 244
  • [8] PrPc depletion in glioblastoma patient derived xenograft cells by CRISPR/Cas9
    Melo Escobar, Maria Isabel
    Coelho, Barbara Paranhos
    Prado, Mariana Brandao
    Iglesia, Rebeca
    Lopes, Marilene Hohmuth
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Improved engraftment of human peripheral blood mononuclear cells in NOG MHC double knockout mice generated using CRISPR/Cas9
    Ka, Yuyo
    Katano, Ikumi
    Nishinaka, Eiko
    Welcker, Jochen
    Mochizuki, Misa
    Kawai, Kenji
    Goto, Motohito
    Tomiyama, Kayo
    Ogura, Tomoyuki
    Yamamoto, Taichi
    Ito, Mamoru
    Ito, Ryoji
    Takahashi, Riichi
    IMMUNOLOGY LETTERS, 2021, 229 : 55 - 61
  • [10] Tandem repeat knockout utilizing the CRISPR/Cas9 system in human cells
    Lv, Qingyan
    Lai, Liangxue
    Yuan, Lin
    Song, Yuning
    Sui, Tingting
    Li, Zhanjun
    GENE, 2016, 582 (02) : 122 - 127
12345